| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72de2e152ca094e277ffae4e6714e384 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6929
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 |
| filingDate |
2018-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f43aaeaa1fdfa1581a833380f2b10152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ab0eb3dbde7952a760a63af975b011a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eab53c66970bf26fa92f2668576fd26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f309a6e45e32e2d4b0f90e865abb7968 |
| publicationDate |
2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2018172386-A |
| titleOfInvention |
LEDGF peptides and their formulations for the treatment of degenerative disorders |
| abstract |
Provided is a peptide having an N-terminus of long lens epithelium-derived growth factor (LEDGF) having antiprotein aggregation activity. (A) a first peptide consisting essentially of the N-terminal amino acid of LEDGF, wherein the N-terminal amino acid is amino acids 1 to 326; (b) at least relative to the amino acid sequence of the first peptide; A second peptide having an amino acid sequence with 90% sequence identity, (c) having an N-terminal stress-related binding domain and a TAT binding domain of full-length LEDGF, and at least 90 relative to the amino acid sequence of the first peptide A purified peptide of a third peptide having an amino acid sequence with% sequence identity, or (d) a fourth peptide having the amino acids 1 to 326 with a protein tag, wherein the purified peptide is biosynthetic or produced and A purified peptide that does not show reduced biological activity or stability to full length LEDGF during purification. [Selection] Figure 1 |
| priorityDate |
2012-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |